STAT+: 931 days. The drug approval scandal hiding in plain sight

The prolonged wait of over two years for the FDA to approve Northwest Biotherapeutics' brain cancer treatment highlights a troubling trend in drug approval processes. This delay not only raises questions about the efficiency and transparency of regulatory oversight but also underscores the potential suffering of patients waiting for life-saving therapies. The scandal here is not just the delay but the lack of clear communication and accountability from regulatory bodies, which could have broader implications for patient trust and the future of drug development. This case serves as a stark reminder of the urgent need for reforms to ensure timely and fair drug evaluations.